Children who live in areas with natural spaces (e.g., forests, parks, backyards) from birth may experience fewer emotional issues between the ages of 2 and 5, according to a study published in JAMA Network Open.
Apr 10, 2024
0
34
Newly published research from the University of Houston College of Pharmacy reveals an alarming trend in diabetic medication expenditures. While pharmaceutical spending in the U.S. has long been recognized as higher than ...
Apr 10, 2024
0
0
Researchers from the Institute of Environmental Medicine at Karolinska Institutet have found that low influence and opportunities for development at work (job control) and heavy physical workload are important explanatory ...
Apr 10, 2024
0
0
The Canadian Cardiovascular Society (CCS) Fitness to Drive Guidelines have been updated to provide the latest advice on driving restrictions for private and commercial drivers. Using the CCS Risk of Harm formula and available ...
Apr 10, 2024
0
0
A new study from the University of Pennsylvania School of Nursing's Center for Health Outcomes and Policy Research (CHOPR)—published in JAMA Network Open—showed that, aside from retirements, poor working conditions are ...
Apr 9, 2024
1
5
Chimeric antigen receptor-T cell therapy (CAR-T cell therapy) could provide a revolutionary approach to organ transplantation for patients who are hard to match and susceptible to rejection, Mayo Clinic researchers discovered.
Apr 9, 2024
0
0
As part of a comprehensive effort to improve cancer screenings among diverse communities, Penn Medicine's Abramson Cancer Center (ACC) Community Outreach and Engagement team developed a culturally sensitive educational video ...
Apr 9, 2024
0
0
A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19.
Apr 8, 2024
0
45
New data presented by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene ...
Apr 8, 2024
0
1
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results ...
Apr 8, 2024
0
0
